Despite an isolated clinical success of trastuzumab and lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive disease, most other targeted agents have been proved of modest or no clinical efficacy in various solid cancers [1, 2]. Continuing the research, clinical, and public health strategy on “one agent for all patients” harms

public health and costs, public and private insurances, and community. Only pharmaceutical industry has major financial gains from the clinical routine use of highly expensive targeted “therapy”. Perhaps a few patients may benefit. Nevertheless, the vast majority of patients experience an unnecessary overtreatment with potential adverse effects [1, 2].